Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Diagnostic, Prognostic and Predictive Factors of Response in the Era of Precision Oncology in Breast Cancer
In the last couple of decades, the study of the cancer genome and the progressive implementation of next-generation sequencing platforms have provided the Scientific and Oncology communities with a multitude of data, technologies, diagnostic, prognostic, and predictive tools that have been revolutionizing the way we can study, diagnose and treat cancer, including breast tumors. For example, genomic tests can now refine the prognosis of early-stage breast cancer patients beyond standard clinicopathological features and help guide escalated or de-escalated treatment choices. The identification of the molecular intrinsic subtypes might also be helpful in guiding treatment choices in advanced hormone receptor-positive disease. The identification of germline mutations in BRCA1 or BRCA2 has led to the development and introduction of PARP inhibitors for the treatment of advanced and early-stage breast cancer, along with personalized follow-up and prophylactic surgical procedures for patients with or without cancer, carrying such mutations.
Methods in Breast Cancer
Frontiers in Oncology is delighted to present the Methods in series of article collections. Methods in Breast Cancer will publish high-quality methodical studies on key topics in the field. It aims to highlight recent advances in the field, whilst emphasizing important directions and new possibilities for future inquiries. The Methods in Breast Cancer collection aims to highlight the latest experimental techniques and methods used to investigate fundamental questions in Breast Cancer. Review Articles or Opinion Articles on methodologies or applications including the advantages and limitations of each are welcome. This Research Topic includes technologies and up-to-date methods which help aim to help advance science. Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
lncRNAs in Cancer Metastasis and Therapy Resistance
lncRNAs (long non-coding RNAs) are the relatively longer (more than 200 nucleotides long) subtypes of ncRNAs (non-coding RNAs) i.e the RNAs that do not code for any proteins. However, even without themselves being translated, lncRNAs impact the cellular gene expressions and functions in ways that are just beginning to be explored. The metastasis of human cancers as well as acquired resistance against the administered therapeutics are two major factors responsible for the cancer-associated mortality.
